Skip to contentS
Syndax Pharmaceuticals Inc
S
SNDXSyndax Pharmaceuticals Inc Q3 2021 · 10-Q
Revenue$12.38M$12.38M+3,165.2% vs Q3 2020 Net Income-$20.64M-$20.64MN/M vs Q3 2020 EPS Diluted-$0.40-$0.40N/M vs Q3 2020 Operating Income-$20,032,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Syndax Pharmaceuticals Inc · CIK 1395937 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-161.9%+5076.4 pt vs Q3 2020
Net margin-166.8%+5225.6 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 15, 2021 · 46 d after period end